ScreenerHero
PYPDPolyPid Ltd.
NAS · US · Healthcare · Biotechnology · polypid.com
5.080USDMkt Cap: 103.18M $P/E: —

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
ARWR
Arrowhead Pharmaceuticals, Inc.
$12.59BUSD

Key Statistics

Company
Market Cap103.18M $
Enterprise Value96.77M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.17M $
Revenue/Share—
Last Price5.080 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.14
PEG—
EV/EBITDA-3.21
EV/Revenue—
P/S—
P/B19.17
EPS (TTM)-1.32
EPS (Forward)-1.23
52W Range
4.96075% of range5.120
52W High5.120 USD
52W Low4.960 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-311.39%
ROA-153.18%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.88M $
CapEx (TTM)210.00K $
FCF Margin—
FCF Yield-16.83%
Net Debt-4.99M $
Net Debt/EBITDA0.17
Balance Sheet
Debt/Equity0.25
Current Ratio1.35
Quick Ratio0.99
Book Value/Sh0.2650 USD
Cash/Share0.3230 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateSep 21, 2023
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.75 USD
Upside (mean)+131.3%
Target Range8.000 USD – 14.00 USD
$8.000+131.3% to mean$14.00
# Analysts4
Ownership
Shares Out.20.31M
Float12.16M
Insiders20.04%
Institutions33.69%
Short Interest
Short Ratio1.3d
Short % Float2.94%
Short % Out.2.15%
Shares Short412.85K
Short (prev mo.)84.50K
Technical
SMA 504.742 (+7.1%)
SMA 2004.421 (+14.9%)
Beta1.39
S&P 52W Chg21.00%
Avg Vol (30d)129.44K
Avg Vol (10d)155.03K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—